title: Reduction of radioantibody-induced myelotoxicity in hamsters by recombinant interleukin-1.
abstract: Recombinant human interleukin 1 (IL-1) administered i.p. to tumor-bearing hamsters results in a dose-dependent 2- to 5-fold increase in total peripheral white blood cells. These levels remain elevated for 2 to 3 wk and then decline to base-line levels. Pretreatment of animals with similar doses of IL-1 prevents radioimmunotherapy-induced destruction of the radiosensitive hematopoietic system. Furthermore, recovery from radio-immunotherapy-induced myelosuppression is possible if animals are given IL-1 1 wk after radioimmunotherapy treatment. Thus, both protection and rescue from the hematopoietic damage associated with radioantibody treatment are feasible by pre- or posttreatment with IL-1.
authors.affiliation: Center for Molecular Medicine and Immunology, University of Medicine and Dentistry of New Jersey, Newark 07103.
authors.forename: R D
authors.initials: RD
authors.lastname: Blumenthal
authors.forename: R M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: D J
authors.initials: DJ
authors.lastname: Snyder
authors.forename: H J
authors.initials: HJ
authors.lastname: Hansen
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D000818:Animals; D001853:Bone Marrow / Q000187:drug effects*; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D005260:Female; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D007116:Immunization, Passive; D000922:Immunotoxins / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000633:toxicity*; D007958:Leukocyte Count; D008647:Mesocricetus; D011994:Recombinant Proteins / Q000633:toxicity
chemical_list: D000922:Immunotoxins; D007375:Interleukin-1; D011994:Recombinant Proteins